Unlocking the breakthrough potential of targeted radiopharmaceuticals
Next-generation precision radiopharmaceuticals
Developing targeted alpha-based radiopharmaceuticals for the treatment of cancer patients.
Aktis Oncology is committed to improving outcomes for cancer patients by pioneering a new class of targeted radiopharmaceuticals addressing prevalent tumor types that historically have been beyond the reach of radiopharmaceuticals.
We have built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy for broad patient populations with significant unmet needs.
Platform
Pipeline
Aktis Oncology is committed to improving outcomes for cancer patients by pioneering a new class of targeted radiopharmaceuticals addressing prevalent tumor types that historically have been beyond the reach of radiopharmaceuticals.
We have built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy for broad patient populations with significant unmet needs.
Aktis Oncology is committed to improving outcomes for cancer patients by pioneering a new class of targeted radiopharmaceuticals addressing prevalent tumor types that historically have been beyond the reach of radiopharmaceuticals.
We have built a proprietary miniprotein radioconjugate platform that aims to safely confer breakthrough efficacy for broad patient populations with significant unmet needs.
Join us
With scientific excellence and a passion for innovation, we are discovering and developing therapies that have the potential to further transform the cancer treatment paradigm for large patient populations.
